作者：
Michelle,Crouthamel [1]
;
Robert J,Mather [2]
;
Suraj,Ramachandran [3]
;
Kai,Bode [3]
;
Godhuli,Chatterjee [4]
;
Luis,Garcia-Gancedo [5]
;
Joseph,Kim [6]
;
Rinol,Alaj [7]
;
Matthew F,Wipperman [7]
;
Lada,Leyens [8]
;
Henrik,Sillen [9]
;
Tina,Murphy [10]
;
Michael,Benecky [11]
;
Brandon,Maggio [12]
;
Thomas,Switzer [13]
作者单位：
Digital Health & Innovation, Global Clinical Development, AbbVie Inc., North Chicago, Illinois, USA.
[1]
Early Clinical Development, Pfizer Inc., Cambridge, Massachusetts, USA.
[2]
Global Regulatory Affairs and Clinical Safety (SR), MRL (KB), Merck & Co, Inc., Kenilworth, New Jersey, USA.
[3]
Clinical Study Unit (India-South East Asia Cluster), Sanofi Healthcare India Private Limited, Mumbai, India.
[4]
Value Evidence and Outcomes, GSK, Stevenage, United Kingdom.
[5]
Translational Technology and Innovation, Office of Digital Health, Eli Lilly and Company, Indianapolis, Indiana, USA.
[6]
Clinical Outcomes Assessment and Patient Innovation, Global Study Strategy & Optimization (RA), Precision Medicine, Early Clinical Development & Experimental Sciences (MFW), Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
[7]
Product Development Regulatory, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
[8]
Digital Health R&D, AstraZeneca, Mölndal, Sweden.
[9]
Regulatory Affairs Innovation, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
[10]
Global Regulatory Affairs, UCB Biosciences, Inc., Raleigh, North Carolina, USA.
[11]
Digital Trials - Global Clinical Operations, Boehringer-Ingelheim, Ridgefield, Connecticut, USA.
[12]
Early Clinical Development Informatics, Genentech, South San Francisco, California, USA.
[13]
DOI
10.1159/000518024
PMID
34703974
发布时间
2021-10-28
换一批
换一批
